• Product name

    Recombinant human MMP13 protein (Active)
    See all MMP13 proteins and peptides
  • Biological activity

    This enzyme has a specific activity of ≥200 mU/mg based on its ability to hydrolyze a FRET-based MMP-13 quenched substrate and results in increase of fluorescence, which can be detected at Ex/Em = 325/393 nm.

    One unit is the amount of enzyme that will hydrolyze 1.0 µmole of MMP-13 substrate per minute at pH 7.5 and 37ºC. 

  • Purity

    > 95 % SDS-PAGE.

  • Expression system

    Escherichia coli
  • Accession

  • Protein length

    Protein fragment
  • Animal free

  • Nature

    • Species

    • Sequence

    • Predicted molecular weight

      21 kDa including tags
    • Amino acids

      104 to 274
    • Tags

      His tag C-Terminus


Our Abpromise guarantee covers the use of ab227435 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications


    Functional Studies

  • Form

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Store at -20°C. Avoid freeze / thaw cycle.

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

  • Reconstitution
    Reconstitute the lyophilized protein in 30% glycerol to a final concentration of 1.0 mg/ml and incubate the reconstituted protein at 25 °C for 15 minutes. Store in working aliquots at -20°C.

General Info

  • Alternative names

    • CLG 3
    • CLG3
    • Collagenase 3
    • Collagenase3
    • MANDP1
    • Matrix metallopeptidase 13 (collagenase 3)
    • Matrix Metalloproteinase 13
    • Matrix metalloproteinase-13
    • MMP 13
    • MMP-13
    • Mmp13
    • MMP13_HUMAN
    see all
  • Function

    Degrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process.
  • Tissue specificity

    Seems to be specific to breast carcinomas.
  • Involvement in disease

    Defects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.
    Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
  • Sequence similarities

    Belongs to the peptidase M10A family.
    Contains 4 hemopexin-like domains.
  • Domain

    The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
  • Cellular localization

    Secreted > extracellular space > extracellular matrix.
  • Information by UniProt


  • The activity of ab227435 is ≥ 200 mU/mg based on its ability to hydrolyze a FRET-based MMP-13 substrate.

  • 4-20% SDS-PAGE analysis of 5 µg ab227435.

    Recombinant protein loaded under reducing conditions and stained with Coomassie Blue. 

    The protein shows a predicted MW of ~ 20.5 kDa.


ab227435 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab227435.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact

Sign up